Arecor Therapeutics PLC Arecor Appoints Chief Business Officer (3842V)
April 05 2023 - 2:00AM
UK Regulatory
TIDMAREC
RNS Number : 3842V
Arecor Therapeutics PLC
05 April 2023
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR APPOINTS DR. MANJIT RAHELU AS CHIEF BUSINESS OFFICER
- Manjit is an accomplished strategic deal-maker bringing 25+
years of scientific, commercial and financial experience across
major global pharmaceutical and biotechnology companies,
specialising in product in and out-licensing, commercial strategy,
accelerating growth and M&A
- Will play a key role in building and executing Arecor's
ambitious commercialisation and growth plans as pipeline of
proprietary and partnered products advances
Cambridge, UK, 5 April 2023: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, today announces the appointment of Dr.
Manjit Rahelu as Chief Business Officer, with immediate effect.
Sarah Howell, Chief Executive Officer at Arecor, said: "I am
delighted to welcome Manjit, who brings extensive experience
nurturing the growth of companies and driving deals to commercial
success. We continue to make significant progress across our
in-house proprietary programmes, including our clinical stage
diabetes products as well as our pharma collaborations and, with
several important upcoming milestones, Manjit will play a key role
in meeting our strategic goal to build a significant
self-sustaining biopharmaceutical company."
Manjit is an accomplished strategic deal maker, with a strong
scientific background and over 25 years of technical, commercial
and financial experience across large and mid-sized pharmaceutical
and biotechnology companies. He brings extensive business
development experience in product focused clinical-stage licensing
and M&A and, as a member of Arecor's Executive team, will shape
and oversee the Group's business and corporate development
strategy.
Dr. Manjit Rahelu, Chief Business Officer at Arecor, added:
"Arecor has a clear business strategy and has built both a valuable
in-house portfolio of proprietary product candidates and an
impressive number of partnerships with leading pharmaceutical and
biotechnology companies - all powered by its novel platform
technology. I look forward to supporting the Group's growth towards
becoming a world leading and self-sustaining biopharmaceutical
company."
Most recently, Manjit founded and served as Partner for Alcheme
Advisors, supporting early-stage businesses on a variety of
business development, strategy and optimisation projects. Prior to
this, he held the role of Chief Business Officer and Chief
Operating Officer at Calchan, a UK biotechnology company focussed
on the development of novel molecules targeting pain and
inflammation. Here, he oversaw the shaping and implementing of the
organisation's strategy, processes, and infrastructure, as well as
leading business development efforts.
Manjit also served as Vice President Business Development at
Convergence Pharmaceuticals, where, as a member of the leadership
team, he helped to shape the company's growth strategy, with
primary responsibility for leading business development initiatives
to commercialise its chronic pain assets. He played a pivotal role
in cementing the sale of Convergence to Biogen for GBP675 million
in 2015. Earlier in his career, he held positions with increasing
responsibilities at a variety of life science companies including
Sanofi, Allergy Therapeutics and UCB.
Manjit holds a BSc Hons in Biochemistry from the University of
Sussex and a PhD in Immunology from the University of
Birmingham.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD
and Broker)
Freddy Crossley, Emma Earl (Corporate Tel: +44 (0) 20 7886 2500
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Lindsey Tel: +44 (0) 20 3709 5700
Neville Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
group transforming patient care by bringing innovative medicines to
market through the enhancement of existing therapeutic products. By
applying our innovative proprietary formulation technology
platform, Arestat(TM), we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat(TM) platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAXLLEEDDEFA
(END) Dow Jones Newswires
April 05, 2023 02:00 ET (06:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jul 2023 to Jul 2024